This is a working overview of Certificate of analysis, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-18. Anything still debated is marked as such rather than presented as settled.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
In 1969, the Dubna team carried out chemical experiments on element 102 and concluded that it behaved as the heavier homologue of ytterbium. The Russian scientists proposed the name joliotium (Jo) for the new element after Irène Joliot-Curie, who had recently died, creating an element naming controversy that would not be resolved for several decades, with each group using its own proposed names. In 1992, the IUPAC-IUPAP Transfermium Working Group (TWG) reassessed the claims of discovery and concluded that only the Dubna work from 1966 correctly detected and assigned decays to nuclei with atomic number 102 at the time. The Dubna team are therefore officially recognized as the discoverers of nobelium, although it is possible that it was detected at Berkeley in 1959. This decision was criticized by Berkeley the following year, calling the reopening of the cases of elements 101 to 103 a "futile waste of time", while Dubna agreed with IUPAC's decision. In 1994, as part of an attempted resolution to the element naming controversy, IUPAC ratified names for elements 101–109. For element 102, it ratified the name nobelium (No) on the basis that it had become entrenched in the literature over the course of 30 years and that Alfred Nobel should be commemorated in this fashion. Because of outcry over the 1994 names, which mostly did not respect the choices of the discoverers, a comment period ensued, and in 1995 IUPAC named element 102 flerovium (Fl) as part of a new proposal, after either Georgy Flyorov or his eponymous Flerov Laboratory of Nuclear Reactions.
===== Czech Republic ===== As of May 2023, the State Agricultural and Food Inspection of the Czech Republic is putting together broad regulations regarding a ban on CBD products. They will make it illegal to sell products containing cannabidiol and other cannabinoids derived from hemp, as a result of EU Novel Food Regulation. In case of Czech Republic, European Industrial Hemp Association has submitted an official request to the Czech Republic to recognize natural hemp extracts with cannabinoids as traditional food.
In February 2011, the European Commission's Committee for Medicinal Products for Human Use approved the product for the treatment of Dupuytren's contracture in adults with a palpable cord by 'properly trained' doctors. Pfizer was reported to be working with Europe's national medicines regulatory bodies to launch the new treatment, hoping doctors could prescribe the treatment by late 2011. On November 7, 2012, BioSpecifics announced "BioSpecifics Technologies Corp. : Reports Third Quarter 2012 Financial Results". Auxilium's submission of a License Application to the FDA for Xiaflex for the potential treatment of Peyronie's disease, an excess of inelastic collagen causing penile curvature deformity. The FDA approved Xiaflex for the treatment of Peyronie’s disease in December 2013. Following this, Xiapex gained EU approval for the treatment of Peyronie’s disease in February 2015, making it the first and only biologic therapy indicated for the treatment of Peyronie's disease. Auxilium has also reported additional trials for potential use of Xiaflex are underway for the treatment of frozen shoulder, cellulite reductions and both human and canine lipomas. In March 2020, the Swedish manufacturer abruptly withdrew distribution of this drug in Europe for commercial reasons. Collagenase is no longer available on the National Health System except as part of a small clinical trial.
=== Controversies on the nature and reality of fibromyalgia === In the past, fibromyalgia was a disputed diagnosis. Rheumatologist Frederick Wolfe, lead author of the 1990 paper that first defined the diagnostic guidelines for fibromyalgia, stated in 2008 that he believed it "clearly" was not a disease but instead a physical response to depression and stress. In 2013, Wolfe added that its causes "are controversial in a sense" and "there are many factors that produce these symptoms – some are psychological and some are physical and it does exist on a continuum." Some members of the medical community did not consider fibromyalgia a disease because of a lack of abnormalities on physical examination and the absence of objective diagnostic tests. In the past, some psychiatrists viewed fibromyalgia as a type of affective disorder, or a somatic symptom disorder. These controversies did not engage healthcare specialists alone; some patients objected to fibromyalgia being described in purely somatic terms. As of 2022, neurologists and pain specialists tended to view fibromyalgia as a real pathology. It was mostly seen as due to dysfunction of muscles and connective tissue as well as functional abnormalities in the central nervous system. Rheumatologists defined the syndrome in the context of "central sensitization" – heightened brain response to normal stimuli in the absence of disorders of the muscles, joints, or connective tissues.
Shear-thickening (dilatant) liquids, whose viscosity increases with the rate of shear strain. Shear-thinning liquids, whose viscosity decreases with the rate of shear strain. Thixotropic liquids, that become less viscous over time when shaken, agitated, or otherwise stressed. Rheopectic liquids, that become more viscous over time when shaken, agitated, or otherwise stressed. Bingham plastics that behave as a solid at low stresses but flow as a viscous fluid at high stresses. Trouton's ratio is the ratio of extensional viscosity to shear viscosity. For a Newtonian fluid, the Trouton ratio is 3. Shear-thinning liquids are very commonly, but misleadingly, described as thixotropic. Viscosity may also depend on the fluid's physical state (temperature and pressure) and other, external, factors. For gases and other compressible fluids, it depends on temperature and varies very slowly with pressure. The viscosity of some fluids may depend on other factors. A magnetorheological fluid, for example, becomes thicker when subjected to a magnetic field, possibly to the point of behaving like a solid.
Sources: en.wikipedia.org
== Musicians, composers, and lyricists == Burnet Tuthill (1909), musicologist, conductor, founder and secretary of the National Association of Schools of Music Roy Webb (1910), composer for Notorious and Abe Lincoln in Illinois Richard Hale (1914), opera and concert singer; narrator, Peter and the Wolf Oscar Hammerstein II (1916), lyricist for Show Boat, Oklahoma! and The King and I, among other Broadway musical hits Howard Dietz (1917), director of publicity for MGM and lyricist for "Dancing in the Dark" Lorenz Hart (1918), lyricist for Pal Joey and other Broadway musical hits Richard Rodgers* (1923), composer and collaborator with Lorenz Hart and Oscar Hammerstein II; wrote music for Carousel, The Sound of Music, and Victory at Sea, among many others; one of the only two people to have won an Emmy, a Grammy, an Oscar, a Tony Award, and a Pulitzer Prize Elie Siegmeister (1927), composer, music teacher, writer on music Richard Franko Goldman (1930), composer, music professor, president of the Peabody Institute 1969–1977 Milton Katims (1930), conductor, music director of the Seattle Symphony 1954–1976 Mordecai Bauman (1935), baritone Emerson Buckley (1936), conductor, The Crucible, The Ballad of Baby Doe; director of the Florida Grand Opera 1950–1973 Eddie Sauter (1936), jazz musician Elliott Schwartz (1936), composer and professor emeritus of Bowdoin College John La Touche* (1937), lyricist for Cabin in the Sky and The Golden Apple Howard Shanet (1939), conductor and composer, former head of Columbia University's music department Leonard B.
Wound licking is an instinctive response in humans and many other animals to cover an injury or second degree burn with saliva. Dogs, cats, small rodents, horses, and primates, including humans, all lick wounds. Saliva contains tissue factor which promotes the blood clotting mechanism. The enzyme lysozyme is found in many tissues and is known to attack the cell walls of many gram-positive bacteria, aiding in defense against infection. Tears are also beneficial to wounds due to the lysozyme enzyme. However, there are also infection risks due to bacteria in the mouth.
===== Emergency department visits ===== Emergency room (ER) admissions associated with cannabis use rose significantly from 2012 to 2016; adolescents from age 12–17 had the highest risk. At one Colorado medical center following legalization, approximately two percent of ER admissions were classified as cannabis users. The symptoms of one quarter of these users were partially attributed to cannabis (a total of 2567 out of 449,031 patients); other drugs were sometimes involved. Of these cannabis admissions, one quarter were for acute psychiatric effects, primarily suicidal ideation, depression, and anxiety. An additional third of the cases were for gastrointestinal issues including cannabinoid hyperemesis syndrome. According to the United States Department of Health and Human Services, there were 455,000 emergency room visits associated with cannabis use in 2011. These statistics include visits in which the patient was treated for a condition induced by or related to recent cannabis use. The drug use must be "implicated" in the emergency department visit, but does not need to be the direct cause of the visit. Most of the illicit drug emergency room visits involved multiple drugs. In 129,000 cases, cannabis was the only implicated drug.
Wilhelm Röntgen's discovery of X-rays in 1895 led to the use of radiographs to locate bullets in wounded soldiers. Survival rates for gunshot wounds improved among US military personnel during the Korean and Vietnam Wars, due in part to helicopter evacuation, along with improvements in resuscitation and battlefield medicine. Similar improvements were seen in US trauma practices during the Iraq War. Military health care providers who return to civilian practice sometimes disseminate military trauma care practices. One such practice is to transfer major trauma cases to an operating theater as soon as possible, to stop internal bleeding. Within the United States, the survival rate for gunshot wounds has increased, leading to declines in the gun death rate in states that have stable rates of gunshot hospitalizations.
A study presented at the annual meeting of the American Geophysical Union in December 2006 asserted that a small-scale regional nuclear war could produce as many direct fatalities as all of World War II and disrupt the global climate for a decade or more. In a regional nuclear conflict scenario in which two opposing nations in the subtropics each used 50 Hiroshima-sized nuclear weapons (c. 15 kiloton each) on major population centers, the researchers predicted fatalities ranging from 2.6 million to 16.7 million per country. The authors of the study estimated that as much as five million tons of soot could be released, producing a cooling of several degrees over large areas of North America and Eurasia (including most of the grain-growing regions). The cooling would last for years and could be "catastrophic", according to the researchers. Either a limited or full-scale nuclear exchange could occur during an accidental nuclear war, in which the use of nuclear weapons is triggered unintentionally. Postulated triggers for this scenario have included malfunctioning early warning devices and/or targeting computers, deliberate malfeasance by rogue military commanders, consequences of an accidental straying of warplanes into enemy airspace, reactions to unannounced missile tests during tense diplomatic periods, reactions to military exercises, mistranslated or miscommunicated messages, and others. A number of these scenarios actually occurred during the Cold War, though none resulted in the use of nuclear weapons.
Sources: en.wikipedia.org
Russ Prize "for automating DNA sequencing that revolutionized biomedicine and forensic science"; the 2011 National Medal of Science, presented at a White House ceremony by President Obama in early 2013; the IEEE Medal for Innovations in Healthcare Technology in 2014, and the 2016 Ellis Island Medal of Honor. In 2017 he received the NAS Award for Chemistry in Service to Society. In 2019 Hood was awarded the IRI Medal, established by the Industrial Research Institute (IRI).
=== Nitrile oxides === Nitrile oxides have the chemical formula RCNO. Their general structure is R−C≡N+−O−. The R stands for any group (typically organyl, e.g., acetonitrile oxide CH3−C≡N+−O−, hydrogen in the case of fulminic acid H−C≡N+−O−, or halogen (e.g., chloroformonitrile oxide Cl−C≡N+−O−). Nitrile oxides are quite different from nitriles and do not arise from direct oxidation of the latter. Instead, they can be synthesised by nitroalkane dehydration, oxime dehydrogenation, or halooxime elimination in base. They are highly reactive in 1,3-dipolar cycloadditions, such as to isoxazoles, and undergo type I dyotropic rearrangement to isocyanates. The heavier nitrile sulfides are extremely reactive and rare, but temporarily form during the thermolysis of oxathiazolones. They react similarly to nitrile oxides.
Therefore, to function effectively they require an absence of maritime crime in order for trade to be uninterrupted, and for their economies to thrive. Sri Lanka has also faced an increase in heroin use within the country, as well as becoming a transit country for trafficking destined for other places. Much of the heroin entering Sri Lanka arrives on fishing boats or by air, often coming through India or Pakistan. The numbers of seizures which Sri Lankan authorities have conducted remains relatively small, meaning that the data collected is not always reliable. Smugglers in Sri Lanka have come from a variety of countries, including Pakistan, India, Iran and the Maldives.
== Effects of the Closure == Madera Community Hospital was the only hospital within a 30 mile radius, thus the closure caused 160,000 Madera residents to not have access to a local emergency room. Many people were faced with driving the 45 minutes to one of the neighboring towns or not receiving proper treatment. Unfortunately, this decision was already made for residents without access to a vehicle or public transportation. Other hospitals in the Central Valley were then stressed by the pressures of taking on all of the patients who would have previously been treated in Madera, which caused significant increases in emergency room wait times. Private ambulance companies from other counties pitched in to help take calls from Madera to transport residents to other hospitals such as Saint Agnes Medical Care (Fresno) and Community Regional Medical Center (Fresno). Not only were the patients redirected, 772 employees across the four locations were laid off when the hospital shuttered its doors.
== History == Trimipramine was developed by Rhône-Poulenc. It was patented in 1959 and first appeared in the literature in 1961. The drug was first introduced for medical use in 1966, in Europe. It was not introduced in the United States until later in 1979 or 1980.
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.